English

Biohaven Pharmaceutical Holding Company Ltd.

EDGAR

BHVN Quarterly report (10-Q) · filed 2022-08-05

55 filing records in this dataset, filed from 2016-11-10 to 2022-08-05. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

215 million USD

2022 Q2 · USD

Exact inputs and evidence

Revenue: 215079000 USD Source

Operating margin

-134.65%

2022 Q2 · %

Exact inputs and evidence

Operating Income: -289597000 USD Source
Revenue: 215079000 USD Source

Operating cash flow

-134 million USD

2022 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -157680000 USD Source
Operating Cash Flow: -23644000 USD Source

Free cash flow

-136 million USD

2022 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -157680000 USD Source
Operating Cash Flow: -23644000 USD Source
Capital Expenditure: 2393000 USD Source
Capital Expenditure: 512000 USD Source

Cash and cash equivalents: 236 million USD 2022-06-30 Source
Exact value

235807000 USD
Long-term debt including current maturities: 765 million USD 2022-06-30 Source
Exact value

764983000 USD
Shares outstanding: 71.1 million shares 2022-06-30 Source
Exact value

71111071 shares

Reported share-count change

9.00% · 5.87 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

65240458 shares · 2021-06-30· Source
71111071 shares · 2022-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

860 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Revenue: 135740000 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 462509000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 272496000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 318852000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 215079000 USD · 2022-04-01 – 2022-06-30 Source

Net income

-847 million USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Net income: -264968000 USD · 2021-01-01 – 2021-03-31 Source
Net income: -210619000 USD · 2021-04-01 – 2021-06-30 Source
Net income: -171816000 USD · 2021-07-01 – 2021-09-30 Source
Net income: -846586000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -647403000 USD · 2021-01-01 – 2021-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-08-05.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2021-12-31
Operating income: 6 of 11 periods available· newest 2021-12-31
Net income: 4 of 11 periods available· newest 2021-12-31
Operating cash flow: 6 of 11 periods available· newest 2021-12-31
Capital expenditure: 6 of 11 periods available· newest 2021-12-31
Total assets: 4 of 11 periods available· newest 2021-12-31
Total liabilities: 4 of 11 periods available· newest 2021-12-31
Current assets: 4 of 11 periods available· newest 2021-12-31
Current liabilities: 4 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2021-12-31
Shares outstanding: 4 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+626.9%

Prior period

USD 63.63 million

2020-01-01 – 2020-12-31
Current period

USD 462.51 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

462509000 − 63627000 = 398882000 USD

63627000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
462509000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Year-over-year change in Revenue: 398882000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 462509000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1556473 Filing: 000168981322000014 Input fundies:Revenue: 63627000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1557671 Filing: 000168981322000014
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 79.79 million

Prior period

−USD 766.8 million

2020-01-01 – 2020-12-31
Current period

−USD 846.59 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-846586000 − -766796000 = -79790000 USD

-766796000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-846586000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Year-over-year change in Net income: -79790000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -846586000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#2923934 Filing: 000168981322000014 Input fundies:NetIncome: -766796000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#2925186 Filing: 000168981322000014
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 128.22 million

Prior period

−USD 702.88 million

2020-01-01 – 2020-12-31
Current period

−USD 831.1 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-831100000 − -702879000 = -128221000 USD

-702879000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-831100000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Year-over-year change in Operating cash flow: -128221000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -831100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1908482 Filing: 000168981322000014 Input fundies:OperatingCashFlow: -702879000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1909755 Filing: 000168981322000014
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-27.5%

Prior period

USD 2.37 million

2020-01-01 – 2020-12-31
Current period

USD 1.72 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

1718000 − 2370000 = -652000 USD

2370000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
1718000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Year-over-year change in Capital expenditure: -652000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1718000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1922868 Filing: 000168981322000014 Input fundies:CapitalExpenditure: 2370000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1923851 Filing: 000168981322000014
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 462.51 million 100% of revenue
Cost of revenue USD 91.66 million 20% of revenue
Operating expenses USD 1.07 billion 232% of revenue
Operating income −USD 704.04 million −152% of revenue
Tax, interest and other Derived USD 142.54 million 31% of revenue
Net income −USD 846.59 million −183% of revenue

Cash

Operating cash flow −USD 831.1 million −180% of revenue
Capital expenditure USD 1.72 million 0.4% of revenue
Free cash flow Derived −USD 832.82 million −180% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Operating loss: operating costs were 1,114% of revenue.
2021 Operating loss: operating costs were 252% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	0	224554000 Derived	-224554000	16368000 Derived	-240922000	-201306000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -224554000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -240922000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -197141000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 4165000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	0	479122000 Derived	-479122000	49683000 Derived	-528805000	-379865000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -479122000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -528805000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -377331000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2534000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	63627000	709015000 Derived	-645388000	121408000 Derived	-766796000	-705249000 Derived	Source 2020-01-01 – 2020-12-31: 63627000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -645388000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -766796000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -702879000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 2370000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	462509000	1166553000 Derived	-704044000	142542000 Derived	-846586000	-832818000 Derived	Source 2021-01-01 – 2021-12-31: 462509000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -704044000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -846586000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -831100000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1718000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 462.5M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	0	Revenue: 0 Open source
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	63627000	Revenue: 63627000 Open source
20212021-12-31	Revenue	462509000	Revenue: 462509000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

626.9% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 63627000 Open source Revenue: 0 Open source
20212021-12-31	Year over year	626.9%	Revenue: 462509000 Open source Revenue: 63627000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -152.2% 2021

Net margin -183% 2021

Free cash flow margin -180.1% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	Not reported	Operating Income: -224554000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -479122000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	-1,014.3%	Operating Income: -645388000 Open source Revenue: 63627000 Open source
20212021-12-31	Operating margin	-152.2%	Operating Income: -704044000 Open source Revenue: 462509000 Open source
20182018-12-31	Net margin	Not reported	Net Income: -240922000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -528805000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	-1,205.1%	Net Income: -766796000 Open source Revenue: 63627000 Open source
20212021-12-31	Net margin	-183%	Net Income: -846586000 Open source Revenue: 462509000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -197141000 Open source Capital Expenditure: 4165000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -377331000 Open source Capital Expenditure: 2534000 Open source
20202020-12-31	Free cash flow margin	-1,108.4%	Revenue: 63627000 Open source Operating Cash Flow: -702879000 Open source Capital Expenditure: 2370000 Open source
20212021-12-31	Free cash flow margin	-180.1%	Revenue: 462509000 Open source Operating Cash Flow: -831100000 Open source Capital Expenditure: 1718000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -831.1M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-197141000	Operating Cash Flow: -197141000 Open source
20192019-12-31	Operating cash flow	-377331000	Operating Cash Flow: -377331000 Open source
20202020-12-31	Operating cash flow	-702879000	Operating Cash Flow: -702879000 Open source
20212021-12-31	Operating cash flow	-831100000	Operating Cash Flow: -831100000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -832.8M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-201306000	Operating Cash Flow: -197141000 Open source Capital Expenditure: 4165000 Open source
20192019-12-31	Free cash flow	-379865000	Operating Cash Flow: -377331000 Open source Capital Expenditure: 2534000 Open source
20202020-12-31	Free cash flow	-705249000	Operating Cash Flow: -702879000 Open source Capital Expenditure: 2370000 Open source
20212021-12-31	Free cash flow	-832818000	Operating Cash Flow: -831100000 Open source Capital Expenditure: 1718000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

163.4% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	48%	Total Liabilities: 139092000 Open source Total Assets: 290012000 Open source
20192019-12-31	Liabilities / assets	102.2%	Total Liabilities: 351688000 Open source Total Assets: 344264000 Open source
20202020-12-31	Liabilities / assets	148.4%	Total Liabilities: 1019164000 Open source Total Assets: 686975000 Open source
20212021-12-31	Liabilities / assets	163.4%	Total Liabilities: 1760221000 Open source Total Assets: 1077212000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.64× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	13.94×	Current Assets: 272339000 Open source Current Liabilities: 19534000 Open source
20192019-12-31	Current assets / current liabilities	4.96×	Current Assets: 328281000 Open source Current Liabilities: 66173000 Open source
20202020-12-31	Current assets / current liabilities	2.17×	Current Assets: 603406000 Open source Current Liabilities: 277606000 Open source
20212021-12-31	Current assets / current liabilities	1.64×	Current Assets: 876254000 Open source Current Liabilities: 534202000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	−USD 29.5 million Exact value Exact value: -29504000 USD 2016-01-01 – 2016-12-31: -29504000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Biohaven Pharmaceutical Holding Company Ltd. · 2016-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Operating Cash Flow: -29504000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29504000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981319000014/bhvn-20181231.htm#2280729 Filing: 000168981319000014 The citation records this snapshot. The page link may show a newer release later.	USD 26,000 Exact value Exact value: 26000 USD 2016-01-01 – 2016-12-31: 26000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Biohaven Pharmaceutical Holding Company Ltd. · 2016-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Capital Expenditure: 26000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981319000014/bhvn-20181231.htm#2285229 Filing: 000168981319000014 The citation records this snapshot. The page link may show a newer release later.	−USD 29.53 million Calculation and evidence -29504000 − 26000 USD Exact free cash flow: -29530000 USD 2016-01-01 – 2016-12-31: -29504000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 26000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Biohaven Pharmaceutical Holding Company Ltd. · 2016-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Free cash flow: -29530000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29504000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981319000014/bhvn-20181231.htm#2280729 Filing: 000168981319000014 Input fundies:CapitalExpenditure: 26000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981319000014/bhvn-20181231.htm#2285229 Filing: 000168981319000014 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−USD 94.82 million Exact value Exact value: -94815000 USD 2017-01-01 – 2017-12-31: -94815000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Biohaven Pharmaceutical Holding Company Ltd. · 2017-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Operating Cash Flow: -94815000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -94815000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981320000016/bhvn-20191231.htm#2775556 Filing: 000168981320000016 The citation records this snapshot. The page link may show a newer release later.	USD 541,000 Exact value Exact value: 541000 USD 2017-01-01 – 2017-12-31: 541000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Biohaven Pharmaceutical Holding Company Ltd. · 2017-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Capital Expenditure: 541000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 541000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981320000016/bhvn-20191231.htm#2783138 Filing: 000168981320000016 The citation records this snapshot. The page link may show a newer release later.	−USD 95.36 million Calculation and evidence -94815000 − 541000 USD Exact free cash flow: -95356000 USD 2017-01-01 – 2017-12-31: -94815000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 541000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Biohaven Pharmaceutical Holding Company Ltd. · 2017-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Free cash flow: -95356000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -94815000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981320000016/bhvn-20191231.htm#2775556 Filing: 000168981320000016 Input fundies:CapitalExpenditure: 541000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981320000016/bhvn-20191231.htm#2783138 Filing: 000168981320000016 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 240.92 million Exact value Exact value: -240922000 USD 2018-01-01 – 2018-12-31: -240922000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Biohaven Pharmaceutical Holding Company Ltd. · 2018-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Net Income: -240922000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -240922000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981321000024/bhvn-20201231.htm#2719004 Filing: 000168981321000024 The citation records this snapshot. The page link may show a newer release later.	−USD 197.14 million Exact value Exact value: -197141000 USD 2018-01-01 – 2018-12-31: -197141000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Biohaven Pharmaceutical Holding Company Ltd. · 2018-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Operating Cash Flow: -197141000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -197141000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981321000024/bhvn-20201231.htm#1817283 Filing: 000168981321000024 The citation records this snapshot. The page link may show a newer release later.	USD 4.17 million Exact value Exact value: 4165000 USD 2018-01-01 – 2018-12-31: 4165000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Biohaven Pharmaceutical Holding Company Ltd. · 2018-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Capital Expenditure: 4165000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4165000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981321000024/bhvn-20201231.htm#1827831 Filing: 000168981321000024 The citation records this snapshot. The page link may show a newer release later.	−USD 201.31 million Calculation and evidence -197141000 − 4165000 USD Exact free cash flow: -201306000 USD 2018-01-01 – 2018-12-31: -197141000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 4165000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Biohaven Pharmaceutical Holding Company Ltd. · 2018-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Free cash flow: -201306000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -197141000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981321000024/bhvn-20201231.htm#1817283 Filing: 000168981321000024 Input fundies:CapitalExpenditure: 4165000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981321000024/bhvn-20201231.htm#1827831 Filing: 000168981321000024 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 528.81 million Exact value Exact value: -528805000 USD 2019-01-01 – 2019-12-31: -528805000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Biohaven Pharmaceutical Holding Company Ltd. · 2019-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Net Income: -528805000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -528805000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#2926438 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	−USD 377.33 million Exact value Exact value: -377331000 USD 2019-01-01 – 2019-12-31: -377331000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Biohaven Pharmaceutical Holding Company Ltd. · 2019-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Operating Cash Flow: -377331000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -377331000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1911028 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	USD 2.53 million Exact value Exact value: 2534000 USD 2019-01-01 – 2019-12-31: 2534000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Biohaven Pharmaceutical Holding Company Ltd. · 2019-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Capital Expenditure: 2534000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2534000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1924834 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	−USD 379.87 million Calculation and evidence -377331000 − 2534000 USD Exact free cash flow: -379865000 USD 2019-01-01 – 2019-12-31: -377331000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2534000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Biohaven Pharmaceutical Holding Company Ltd. · 2019-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Free cash flow: -379865000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -377331000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1911028 Filing: 000168981322000014 Input fundies:CapitalExpenditure: 2534000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1924834 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 766.8 million Exact value Exact value: -766796000 USD 2020-01-01 – 2020-12-31: -766796000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Biohaven Pharmaceutical Holding Company Ltd. · 2020-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Net Income: -766796000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -766796000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#2925186 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	−USD 702.88 million Exact value Exact value: -702879000 USD 2020-01-01 – 2020-12-31: -702879000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Biohaven Pharmaceutical Holding Company Ltd. · 2020-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Operating Cash Flow: -702879000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -702879000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1909755 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	USD 2.37 million Exact value Exact value: 2370000 USD 2020-01-01 – 2020-12-31: 2370000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Biohaven Pharmaceutical Holding Company Ltd. · 2020-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Capital Expenditure: 2370000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2370000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1923851 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	−USD 705.25 million Calculation and evidence -702879000 − 2370000 USD Exact free cash flow: -705249000 USD 2020-01-01 – 2020-12-31: -702879000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2370000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Biohaven Pharmaceutical Holding Company Ltd. · 2020-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Free cash flow: -705249000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -702879000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1909755 Filing: 000168981322000014 Input fundies:CapitalExpenditure: 2370000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1923851 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 846.59 million Exact value Exact value: -846586000 USD 2021-01-01 – 2021-12-31: -846586000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Net Income: -846586000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -846586000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#2923934 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	−USD 831.1 million Exact value Exact value: -831100000 USD 2021-01-01 – 2021-12-31: -831100000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Operating Cash Flow: -831100000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -831100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1908482 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	USD 1.72 million Exact value Exact value: 1718000 USD 2021-01-01 – 2021-12-31: 1718000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Capital Expenditure: 1718000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1718000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1922868 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.	−USD 832.82 million Calculation and evidence -831100000 − 1718000 USD Exact free cash flow: -832818000 USD 2021-01-01 – 2021-12-31: -831100000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1718000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Biohaven Pharmaceutical Holding Company Ltd. · 2021-12-31 Biohaven Pharmaceutical Holding Company Ltd. (edgar:1689813) Free cash flow: -832818000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1689813?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -831100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1908482 Filing: 000168981322000014 Input fundies:CapitalExpenditure: 1718000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1689813/000168981322000014/bhvn-20211231.htm#1922868 Filing: 000168981322000014 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

55 filings · 1,918 latest values · 1,918 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001689813, 1689813, BHVN, edgar:1689813

Also known as Biohaven Pharmaceutical Holding Co Ltd., Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation